# A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

> **NCT04444141** · PHASE1,PHASE2 · TERMINATED · sponsor: **Akeso** · enrollment: 6 (actual)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **BIOLOGICAL:** AK104

## Key facts

- **NCT ID:** NCT04444141
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-15
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Due to difficuty of erollment and consideration of clinical guideline,The sponsor decided to stop study.
- **Last updated:** 2022-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04444141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04444141, "A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04444141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*